140 related articles for article (PubMed ID: 31623625)
1. Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.
Coleman RL; Scott CAB; Lang Z; Bethel MA; Tuomilehto J; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):135. PubMed ID: 31623625
[TBL] [Abstract][Full Text] [Related]
2. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
[TBL] [Abstract][Full Text] [Related]
3. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
4. Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
Wamil M; McMurray JJV; Scott CAB; Coleman RL; Sun Y; Standl E; Rydén L; Holman RR
Diabetes Res Clin Pract; 2020 Dec; 170():108488. PubMed ID: 33035598
[TBL] [Abstract][Full Text] [Related]
5. Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial.
Gerstein HC; Coleman RL; Scott CAB; Xu S; Tuomilehto J; Rydén L; Holman RR;
Diabetes Care; 2020 Sep; 43(9):2242-2247. PubMed ID: 32641379
[TBL] [Abstract][Full Text] [Related]
6. All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials.
Mannucci E; Gallo M; Pintaudi B; Targher G; Candido R; Giaccari A; Monami M;
Nutr Metab Cardiovasc Dis; 2022 Feb; 32(2):511-514. PubMed ID: 34893404
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.
Cai X; Yang W; Zhou L; Zhang S; Han X; Ji L
Endocrine; 2015 Dec; 50(3):590-7. PubMed ID: 26048437
[TBL] [Abstract][Full Text] [Related]
8. [Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance].
Kawamori R; Tajima N; Iwamoto Y; Kashiwagi A; Shimamoto K; Kaku K
Nihon Rinsho; 2009 Sep; 67(9):1821-5. PubMed ID: 19768922
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
10. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
11. Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Asakura M; Kim J; Asanuma H; Hamasaki T; Tsukahara K; Higashino Y; Ishikawa T; Nakama Y; Koba S; Maruyama Y; Tsujimoto M; Himeno H; Ohkusa T; Fujino S; Shimizu M; Endo T; Yoda S; Muroya T; Murohara T; Ohte N; Suzuki H; Kohno T; Fukui K; Shiono T; Takase H; Uzui H; Nagai Y; Hashimoto Y; Ikeda S; Mizuno S; Tamita K; Fujita M; Satake K; Kinoshita Y; Nunohiro T; Sakagami S; Higaki J; Morii I; Sawada R; Hiasa Y; Shigemasa T; Nakahama M; Sata M; Doi O; Ueda T; Yamada T; Yamanouchi T; Yamaguchi H; Morita Y; Hayashi H; Kitakaze M;
Cardiovasc Drugs Ther; 2017 Aug; 31(4):401-411. PubMed ID: 28779371
[TBL] [Abstract][Full Text] [Related]
12. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study.
Anand SS; Dagenais GR; Mohan V; Diaz R; Probstfield J; Freeman R; Shaw J; Lanas F; Avezum A; Budaj A; Jung H; Desai D; Bosch J; Yusuf S; Gerstein HC;
Eur J Prev Cardiol; 2012 Aug; 19(4):755-64. PubMed ID: 21551215
[TBL] [Abstract][Full Text] [Related]
13. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Harumi Higuchi Dos Santos M; Sharma A; Sun JL; Pieper K; McMurray JJ; Holman RR; Lopes RD
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28087508
[TBL] [Abstract][Full Text] [Related]
14. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
15. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
[TBL] [Abstract][Full Text] [Related]
16. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
[TBL] [Abstract][Full Text] [Related]
18. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
Kawamori R; Tajima N; Iwamoto Y; Kashiwagi A; Shimamoto K; Kaku K;
Lancet; 2009 May; 373(9675):1607-14. PubMed ID: 19395079
[TBL] [Abstract][Full Text] [Related]
19. Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis.
Zhang L; Chen Q; Li L; Kwong JS; Jia P; Zhao P; Wang W; Zhou X; Zhang M; Sun X
Sci Rep; 2016 Sep; 6():32649. PubMed ID: 27596383
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
